Modality
ADC
MOA
GLP-1ag
Target
CDK4/6
Pathway
Fibrosis
SchizophreniaNBSCD
Development Pipeline
Preclinical
~Feb 2015
→ ~May 2016
Phase 1
~Aug 2016
→ ~Nov 2017
Phase 2
~Feb 2018
→ ~May 2019
Phase 3
Aug 2019
→ Dec 2028
Phase 3Current
NCT03651849
2,908 pts·SCD
2019-08→2028-12·Not yet recruiting
2,908 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-12-222.7y awayPh3 Readout· SCD
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P3
Not yet…
Catalysts
Ph3 Readout
2028-12-22 · 2.7y away
SCD
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03651849 | Phase 3 | SCD | Not yet recr... | 2908 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 | |
| CRS-184 | CRISPR Therapeutics | Phase 1/2 | AHR |